New research reveals stem cell therapy significantly lowers heart failure risk in heart attack survivors. Patients receiving ...

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, ...

ASX device and diagnostic companies are intensifying their measures to expedite product rollouts and approvals in the US.

Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

Decision Immediately Expands Access to Heart Failure Therapy with National Coverage for More Than 66 Million[1] PatientsMARLTON, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Impulse Dynamics®, a global ...

Across studies, the rate of sudden death in ibrutinib-treated patients ranged from 0.49 to 0.788 per 100 patient-years, roughly double that seen in comparators. In contrast, pooled analyses of ...

Treatments for asthma, chronic rhinosinusitis with nasal polyps, dyslipidemia, Cushing syndrome, gonorrhea, HSCT-associated thrombotic microangiopathy, marginal zone lymphoma, motion sickness, ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Engineers at MIT say they developed a flexible drug delivery patch for promoting healing and tissue regeneration after heart ...